SynthesisMolecular imaging
A Review of Fluorophores for Fluorescence-Guided Surgery in Breast Cancer.
Synthesis in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Imprecision in breast-conserving surgery results in re-excision in 20% of cases, delaying adjuvant therapy and increasing patient anxiety and financial burden. Fluorescence-guided surgery (FGS) enables real-time tumor visualization and may improve surgical precision. This systematic review evaluates fluorophores investigated for intraoperative navigation in breast cancer. Medline, Embase, Scopus, and Web of Science were searched using "breast cancer," "surgery," "fluorophore," and "near-infrared." Eligible studies investigated in vivo fluorophores for invasive breast cancer in animals or humans. Of 1946 studies, 65 met the inclusion criteria. Extracted data included fluorophore administration, mechanism, optical properties, imaging systems, safety, and diagnostic accuracy. Dual-modality studies were excluded. 58 fluorophores were evaluated across 761 human and 520 animal subjects. Most agents emitted within the near-infrared-I (NIR-I) window (74.1%), while 11 utilized NIR-II imaging for deeper penetration. Indocyanine green (ICG) was the most widely studied fluorophore, demonstrating a pooled clinical tumor-to-background ratio (TBR) of 2.25 ± 0.74 (95% CI 2.10-2.39); sensitivity 80.8% (95% CI 72.5-89.2%); specificity 93.3% (95% CI 88.1-98.6%). IRDye800CW-trastuzumab demonstrated higher pooled TBRs of 4.83 ± 1.77 (95% CI 4.27-5.40). Nanoparticle-based fluorophores showed high contrast but remained preclinical. FGS is rapidly evolving, but no fluorophore has demonstrated optimal performance across translational endpoints; standardized reporting remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.